Stay updated with breaking news from Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
08.08.2022 - First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through corporate restructuring with focus on key clinical ...
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by...
Transferred anti-IL 18 monoclonal antibody product to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK... | August 4, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Announces Second Quarter 2022 Operating and Financial ResultsProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to discuss findings from sepofarsen Illuminate trial...